BACKGROUND: We wished to evaluate the clinical response following @entity855 -Tumor Chemosensitivity Assay ( @entity855 - @entity2974 ) directed salvage chemotherapy in a series of UK @entity1 with advanced @entity43 . The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints. METHODS: From November 1998 to November 2001, 46 @entity1 with pre-treated, advanced @entity43 were given a total of 56 courses of chemotherapy based on in-vitro @entity855 - @entity2974 responses obtained from fresh @entity5 samples or ascites. Forty-four @entity1 were evaluable for results. Of these, 18 @entity1 had clinically platinum resistant disease (relapse < 6 months after first course of chemotherapy). There was evidence of @entity900 resistance in 31 @entity1 from their first @entity855 - @entity2974 . Response to treatment was assessed by radiology, clinical assessment and @entity5 marker level (CA 125). RESULTS: The overall response rate was 59% (33/56) per course of chemotherapy, including 12 complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease. Two @entity1 were not evaluable for response having received just one cycle of chemotherapy: if these were excluded the response rate is 61%. Fifteen @entity1 are still alive. Median progression free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for each @entity1 following the start of @entity2974 -directed therapy was 10.4 months (95% confidence interval 7.9-12.8 months). CONCLUSION: The results show similar response rates to previous studies using @entity855 - @entity2974 directed therapy in recurrent @entity43 . The assay shows high evaluability and this study adds weight to the reproducibility of results from different centres.

Outcome of XXXX -based @entity5 chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent @entity43 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2974 :: ('CHEBI:30956', 'Chemical') :: ['TCA'] @entity855 :: ('MESH:D000255', 'Chemical') :: ['ATP']
@entity855 :: (MESH:D000255,Chemical) :: ['ATP']
